495 related articles for article (PubMed ID: 29578580)
21. Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease.
Tan EK; Cheah SY; Fook-Chong S; Yew K; Chandran VR; Lum SY; Yi Z
Am J Med Genet B Neuropsychiatr Genet; 2005 Aug; 137B(1):1-4. PubMed ID: 15965967
[TBL] [Abstract][Full Text] [Related]
22. Polymorphisms of COMT (c.649G>A), MAO-A (c.1460C>T), NET (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease.
Florczak-Wyspianska J; Rozycka A; Wolny L; Lianeri M; Kozubski W; Dorszewska J
DNA Cell Biol; 2017 Jun; 36(6):501-512. PubMed ID: 28418735
[TBL] [Abstract][Full Text] [Related]
23. Genetic variations in catechol-O-methyltransferase gene are associated with levodopa response variability in Chinese patients with Parkinson's disease.
Zhao C; Wang Y; Zhang B; Yue Y; Zhang J
Sci Rep; 2020 Jun; 10(1):9521. PubMed ID: 32533012
[TBL] [Abstract][Full Text] [Related]
24. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
[TBL] [Abstract][Full Text] [Related]
25. Extending levodopa action: COMT inhibition.
Martínez-Martín P; O'Brien CF
Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
27. [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
Woitalla D; Krüger R; Lorenzl S; Müller T; Oelwein G; Storch A; Wolz M; Wüllner U
Fortschr Neurol Psychiatr; 2020 Sep; 88(9):620-633. PubMed ID: 32588409
[TBL] [Abstract][Full Text] [Related]
28. Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.
Yan JH; Ge YL; Wang PZ; Li W; Jin H; Zhang JR; Chen J; Wang F; Li D; Mao CJ; Li K; Liu CF
Neurosci Lett; 2023 Mar; 801():137140. PubMed ID: 36813078
[TBL] [Abstract][Full Text] [Related]
29. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
[TBL] [Abstract][Full Text] [Related]
30. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
31. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
32. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
[TBL] [Abstract][Full Text] [Related]
33. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
34. The Associations between COMT and MAO-B Genetic Variants with Negative Symptoms in Patients with Schizophrenia.
Madzarac Z; Tudor L; Sagud M; Nedic Erjavec G; Mihaljevic Peles A; Pivac N
Curr Issues Mol Biol; 2021 Jul; 43(2):618-636. PubMed ID: 34287249
[TBL] [Abstract][Full Text] [Related]
35. Current treatment and future prospects of dopa-induced dyskinesias.
Mazzucchi S; Frosini D; Bonuccelli U; Ceravolo R
Drugs Today (Barc); 2015 May; 51(5):315-29. PubMed ID: 26097904
[TBL] [Abstract][Full Text] [Related]
36. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese population.
Kiyohara C; Miyake Y; Koyanagi M; Fujimoto T; Shirasawa S; Tanaka K; Fukushima W; Sasaki S; Tsuboi Y; Yamada T; Oeda T; Shimada H; Kawamura N; Sakae N; Fukuyama H; Hirota Y; Nagai M;
BMC Neurol; 2011 Jul; 11():89. PubMed ID: 21781348
[TBL] [Abstract][Full Text] [Related]
38. The correlation between genetic factors and freezing of gait in patients with Parkinson's disease.
Radojević B; Dragašević-Mišković NT; Marjanović A; Branković M; Milovanović A; Petrović I; Svetel M; Jančić I; Stanisavljević D; Milićević O; Savić MM; Kostić VS
Parkinsonism Relat Disord; 2022 May; 98():7-12. PubMed ID: 35398727
[TBL] [Abstract][Full Text] [Related]
39. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.
Dos Santos EUD; Sampaio TF; Tenório Dos Santos AD; Bezerra Leite FC; da Silva RC; Crovella S; Asano AGC; Asano NMJ; de Souza PRE
J Pharm Pharmacol; 2019 Feb; 71(2):206-212. PubMed ID: 30353564
[TBL] [Abstract][Full Text] [Related]
40. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Oertel W; Schulz JB
J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
